CompletedPhase 4NCT00634569

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

Studying OBSOLETE: Other complex syndrome of primary immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Instituto Grifols, S.A.
Principal Investigator
Mark Ballow, MD
Children's Hospital of Buffalo
Intervention
Flebogamma 5% DIF(biological)
Enrollment
24 enrolled
Eligibility
2-16 years · All sexes
Timeline
20082011

Study locations (7)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00634569 on ClinicalTrials.gov

Other trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for OBSOLETE: Other complex syndrome of primary immunodeficiency

← Back to all trials